Immunoblot Analysis of the Regulation of TNF Receptor Family-Induced NF-κB Signaling by c-IAP Proteins.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2021
Historique:
entrez: 8 7 2021
pubmed: 9 7 2021
medline: 13 1 2022
Statut: ppublish

Résumé

Proper maintenance of organismal homeostasis, development, and immune defense requires precise regulation of survival and signaling pathways. Inhibitor of apoptosis (IAP) proteins are evolutionarily conserved regulators of cell death and immune signaling that impact numerous cellular processes. Although initially characterized as inhibitors of apoptosis, the ubiquitin ligase activity of IAP proteins is critical for modulating various signaling pathways (e.g., NF-κB, MAPK) and cell survival. Cellular IAP1 and 2 regulate the pro-survival canonical NF-κB pathway by ubiquitinating RIP1 and themselves thus enabling recruitment of kinase (IKK) and E3 ligase (LUBAC) complexes. On the other hand, c-IAP1 and c-IAP2 are negative regulators of noncanonical NF-κB signaling by promoting ubiquitination and consequent proteasomal degradation of the NF-κB-inducing kinase NIK. Here we describe the involvement of c-IAP1 and c-IAP2 in NF-κB signaling and provide detailed methodology for examining functional roles of c-IAPs in these pathways.

Identifiants

pubmed: 34236635
doi: 10.1007/978-1-0716-1669-7_7
doi:

Substances chimiques

Inhibitor of Apoptosis Proteins 0
NF-kappa B 0
Receptors, Tumor Necrosis Factor 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-123

Références

Varfolomeev E, Vucic D (2011) Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol 7:633–648
pubmed: 21568679 doi: 10.2217/fon.11.40 pmcid: 21568679
Ndubaku C, Cohen F, Varfolomeev E et al (2009) Targeting inhibitor of apoptosis (IAP) proteins for therapeutic intervention. Future Med Chem 1:1509–1525
pubmed: 21426063 doi: 10.4155/fmc.09.116 pmcid: 21426063
Vaux DL, Silke J (2005) IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6:287–297
pubmed: 15803136 doi: 10.1038/nrm1621 pmcid: 15803136
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
pubmed: 9759494 doi: 10.1146/annurev.biochem.67.1.425 pmcid: 9759494
Pickart CM, Fushman D (2004) Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 8:610–616
pubmed: 15556404 doi: 10.1016/j.cbpa.2004.09.009 pmcid: 15556404
Vucic D, Dixit VM, Wertz IE (2011) Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12:439–452
pubmed: 21697901 doi: 10.1038/nrm3143 pmcid: 21697901
Bertrand MJ, Milutinovic S, Dickson KM et al (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30:689–700
pubmed: 18570872 doi: 10.1016/j.molcel.2008.05.014 pmcid: 18570872
Silke J, Brink R (2010) Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs. Cell Death Differ 17:35–45
pubmed: 19680262 doi: 10.1038/cdd.2009.114 pmcid: 19680262
Varfolomeev E, Goncharov T, Fedorova AV et al (2008) c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFα)-induced NF-κB activation. J Biol Chem 283:24295–24299
pubmed: 18621737 pmcid: 3259840 doi: 10.1074/jbc.C800128200
Varfolomeev E, Goncharov T, Maecker H et al (2012) Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal 5:ra22
pubmed: 22434933 doi: 10.1126/scisignal.2001878 pmcid: 22434933
Varfolomeev E, Vucic D (2008) (Un)expected roles of c-IAPs in apoptotic and NF-κB signaling pathways. Cell Cycle 7:1511–1521
pubmed: 18469528 doi: 10.4161/cc.7.11.5959 pmcid: 18469528
Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195–2224
pubmed: 15371334 doi: 10.1101/gad.1228704 pmcid: 15371334
Scheidereit C (2006) IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 25:6685–6705
pubmed: 17072322 doi: 10.1038/sj.onc.1209934 pmcid: 17072322
Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181–190
pubmed: 12887920 doi: 10.1016/S0092-8674(03)00521-X pmcid: 12887920
Gentle IE, Silke J (2011) New perspectives in TNF-R1-induced NF-kappaB signaling. Adv Exp Med Biol 691:79–88
pubmed: 21153311 doi: 10.1007/978-1-4419-6612-4_8 pmcid: 21153311
Hayden MS, Ghosh S (2014) Regulation of NF-kappaB by TNF family cytokines. Semin Immunol 26:253–266
pubmed: 24958609 pmcid: 4156877 doi: 10.1016/j.smim.2014.05.004
Haas TL, Emmerich CH, Gerlach B et al (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36:831–844
pubmed: 20005846 doi: 10.1016/j.molcel.2009.10.013 pmcid: 20005846
Gerlach B, Cordier SM, Schmukle AC et al (2011) Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471:591–596
pubmed: 21455173 doi: 10.1038/nature09816 pmcid: 21455173
Ikeda F, Deribe YL, Skanland SS et al (2011) SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 471:637–641
pubmed: 21455181 pmcid: 3085511 doi: 10.1038/nature09814
Tokunaga F, Nakagawa T, Nakahara M et al (2011) SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 471:633–636
pubmed: 21455180 doi: 10.1038/nature09815 pmcid: 21455180
Walczak H (2011) TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev 244:9–28
pubmed: 22017428 doi: 10.1111/j.1600-065X.2011.01066.x pmcid: 22017428
Vince JE, Chau D, Callus B et al (2008) TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 182:171–184
pubmed: 18606850 pmcid: 2447903 doi: 10.1083/jcb.200801010
Dejardin E (2006) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72:1161–1179
pubmed: 16970925 doi: 10.1016/j.bcp.2006.08.007 pmcid: 16970925
Varfolomeev E, Blankenship JW, Wayson SM et al (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131:669–681
pubmed: 18022362 doi: 10.1016/j.cell.2007.10.030 pmcid: 18022362
Vallabhapurapu S, Matsuzawa A, Zhang W et al (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9:1364–1370
pubmed: 18997792 pmcid: 2671996 doi: 10.1038/ni.1678
Zarnegar BJ, Wang Y, Mahoney DJ et al (2008) Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 9:1371–1378
pubmed: 18997794 pmcid: 2676931 doi: 10.1038/ni.1676
Zhang J, Webster JD, Dugger DL et al (2019) Ubiquitin ligases cIAP1 and cIAP2 limit cell death to prevent inflammation. Cell Rep 27:2679–2689
pubmed: 31141691 doi: 10.1016/j.celrep.2019.04.111 pmcid: 31141691
Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109–124
pubmed: 22293567 doi: 10.1038/nrd3627 pmcid: 22293567
Morrish E, Brumatti G, Silke J (2020) Future therapeutic directions for smac-mimetics. Cell 9(2):406
doi: 10.3390/cells9020406
Lacasse EC, Mahoney DJ, Cheung HH et al (2008) IAP-targeted therapies for cancer. Oncogene 27:6252–6275
pubmed: 18931692 doi: 10.1038/onc.2008.302 pmcid: 18931692
Flygare JA, Beresini M, Budha N et al (2012) Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 55:4101–4113
pubmed: 22413863 pmcid: 3366583 doi: 10.1021/jm300060k
Jensen S, Seidelin JB, Lacasse EC et al (2020) SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Sci Signal 13(619):eaax8295
pubmed: 32071170 doi: 10.1126/scisignal.aax8295 pmcid: 32071170
Vince JE, Wong WW, Khan N et al (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131:682–693
pubmed: 18022363 doi: 10.1016/j.cell.2007.10.037 pmcid: 18022363
De Almagro MC, Goncharov T, Newton K et al (2015) Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. Cell Death Dis 6:e1800
pubmed: 26111062 pmcid: 4669837 doi: 10.1038/cddis.2015.158
Dynek JN, Goncharov T, Dueber EC et al (2010) c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 29:4198–4209
pubmed: 21113135 pmcid: 3018797 doi: 10.1038/emboj.2010.300
Goncharov T, Hedayati S, Mulvihill MM et al (2018) Disruption of XIAP-RIP2 association blocks NOD2-mediated inflammatory signaling. Mol Cell 69:551–565
pubmed: 29452636 doi: 10.1016/j.molcel.2018.01.016 pmcid: 29452636
Goncharov T, Niessen K, De Almagro MC et al (2013) OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J 32:1103–1114
pubmed: 23524849 pmcid: 3630360 doi: 10.1038/emboj.2013.62
Matsumoto ML, Dong KC, Yu C et al (2012) Engineering and structural characterization of a linear polyubiquitin-specific antibody. J Mol Biol 418:134–144
pubmed: 22227388 doi: 10.1016/j.jmb.2011.12.053 pmcid: 22227388
Matsumoto ML, Wickliffe KE, Dong KC et al (2010) K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell 39:477–484
pubmed: 20655260 doi: 10.1016/j.molcel.2010.07.001 pmcid: 20655260
Newton K, Matsumoto ML, Ferrando RE et al (2012) Using linkage-specific monoclonal antibodies to analyze cellular ubiquitylation. Methods Mol Biol 832:185–196
pubmed: 22350886 doi: 10.1007/978-1-61779-474-2_13 pmcid: 22350886
Newton K, Matsumoto ML, Wertz IE et al (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134:668–678
pubmed: 18724939 doi: 10.1016/j.cell.2008.07.039 pmcid: 18724939

Auteurs

Eugene Varfolomeev (E)

Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA, USA.

Tatiana Goncharov (T)

Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA, USA.

Domagoj Vucic (D)

Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA, USA. domagoj@gene.com.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
STAT3 Transcription Factor Respiratory Syncytial Virus Infections Humans Animals Mice
Respiratory Syncytial Virus Infections Humans Animals Mice STAT3 Transcription Factor
Animals Lung India Sheep Transcriptome

Classifications MeSH